Patents Assigned to Biogen Idec
  • Patent number: 8734795
    Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: May 27, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Xinzhong Wang, Veronique Bailly, Alexey Lugovskoy, Graham K. Farrington, Christilyn Graff, Scott Glaser
  • Patent number: 8728475
    Abstract: Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-? are disclosed, as are other methods.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 20, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Timothy Zheng
  • Publication number: 20140134164
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicants: BIOGEN IDEC INC., GENENTECH, INC.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Patent number: 8722862
    Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: May 13, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
  • Publication number: 20140127195
    Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jane K. Relton, Roy R. Lobb, Eric T. Whalley, Steve P. Adams
  • Patent number: 8709759
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: April 29, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Konrad Miatkowski, Werner Meier
  • Patent number: 8685657
    Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 1, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Yen-Ming Hsu, Susan Kalled
  • Publication number: 20140079697
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: July 2, 2013
    Publication date: March 20, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Ellen GARBER, Carl REID, Jose W. SALDANHA, Herman VAN VLIJMEN
  • Publication number: 20140079701
    Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.
    Type: Application
    Filed: December 22, 2011
    Publication date: March 20, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronoeski, Tigran Dikran Alvazian
  • Publication number: 20140079716
    Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 20, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventor: BIOGEN IDEC MA INC.
  • Patent number: 8673303
    Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 18, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
  • Patent number: 8669345
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: March 11, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Daniel H. S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
  • Publication number: 20140066505
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 6, 2014
    Applicant: Biogen Idec International GmbH
    Inventors: Rajendra Kumar JOSHI, Hans-Peter Strebel
  • Publication number: 20140067308
    Abstract: The present invention provides automated systems and methods for monitoring column performance in process chromatography, and applications thereof. In an embodiment, column performance is monitored by generating a plurality of process values such as, for example, conductivity values or pH values with a detector during a chromatography step transition between a first mobile phase liquid and a second mobile phase liquid. The process values are transformed to form transformed process values in which noise present in the process values is suppressed. Column performance parameters are calculated based on the transformed process values and displayed during movement of the second mobile phase liquid through the chromatography column.
    Type: Application
    Filed: September 30, 2013
    Publication date: March 6, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Paul CUNNIEN, Joydeep GANGULY, Basav GHOSH, Asif LADIWALA, Robert SONG, Jorg THOMMES
  • Publication number: 20140056887
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Applicant: Biogen Idec Inc.
    Inventor: Antonio J. Grillo-Lopez
  • Patent number: 8647625
    Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: February 11, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J. M. Hanf
  • Patent number: 8642040
    Abstract: This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: February 4, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, Vincent Jung
  • Patent number: 8642732
    Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: February 4, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando
  • Publication number: 20140030263
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: Biogen Idec Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Publication number: 20140017262
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof and their use in treating disorders, such as cancer either alone or in combination with other agents.
    Type: Application
    Filed: March 4, 2013
    Publication date: January 16, 2014
    Applicant: Biogen Idec MA Inc.
    Inventor: Michele SANICOLA-NADEL